Certolizumab pegol for induction of remission in Crohn's disease

Clicks: 445
ID: 111310
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 97 articles by views in The Cochrane database of systematic reviews

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small d …
Reference Key
h2019thecertolizumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yamazaki H;So R;Matsuoka K;Kobayashi T;Shinzaki S;Matsuura M;Okabayashi S;Kataoka Y;Tsujimoto Y;Furukawa TA;Watanabe N;;
Journal The Cochrane database of systematic reviews
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/31476018/
Keywords
systematic review National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine Remission Induction randomized controlled trials as topic Antibodies Monoclonal Humanized / therapeutic use* pmid:31476018 pmc6718195 doi:10.1002/14651858.cd012893.pub2 hajime yamazaki ryuhei so norio watanabe certolizumab pegol / therapeutic use* crohn disease / drug therapy* immunologic factors / therapeutic use induction chemotherapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.